I

InDex Pharmaceuticals Holding AB
STO:FLERIE

Watchlist Manager
InDex Pharmaceuticals Holding AB
STO:FLERIE
Watchlist
Price: 45.3 SEK 1.59% Market Closed
Market Cap: 3.5B SEK
Have any thoughts about
InDex Pharmaceuticals Holding AB?
Write Note

InDex Pharmaceuticals Holding AB
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

InDex Pharmaceuticals Holding AB
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Total Current Assets
kr1.1B
CAGR 3-Years
31%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Total Current Assets
kr1.2B
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Total Current Assets
kr3.3B
CAGR 3-Years
72%
CAGR 5-Years
66%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Total Current Assets
kr1.1B
CAGR 3-Years
-10%
CAGR 5-Years
73%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Total Current Assets
kr123.6m
CAGR 3-Years
-24%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Total Current Assets
kr69.5m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

InDex Pharmaceuticals Holding AB
Glance View

Market Cap
3.5B SEK
Industry
Pharmaceuticals

InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

FLERIE Intrinsic Value
5.85 SEK
Overvaluation 87%
Intrinsic Value
Price
I

See Also

What is InDex Pharmaceuticals Holding AB's Total Current Assets?
Total Current Assets
1.1B SEK

Based on the financial report for Sep 30, 2024, InDex Pharmaceuticals Holding AB's Total Current Assets amounts to 1.1B SEK.

What is InDex Pharmaceuticals Holding AB's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
55%

Over the last year, the Total Current Assets growth was 176%. The average annual Total Current Assets growth rates for InDex Pharmaceuticals Holding AB have been 31% over the past three years , 55% over the past five years .

Back to Top